M&A: Roche Buys RXDX to strength oncology pipeline. 74% premium • Looking to broaden its oncology portfolio, Swiss healthcare firm Roche (OTCQX:RHHBY) is buying U.S. cancer drugmaker Ignyta (NASDAQ:RXDX) for $1.7B. • Roche will pay $27 per share for Ignyta, representing a premium of about 74% to the stock's closing price on Thursday. • The U.S. company has a suite of drugs in early stage development that use gene therapy to kill off underlying diseases that drive cancer tumor growth.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.